Vaccines and Related Biological Products Advisory Committee Meeting June 7, 2022 FDA Briefing Document Novavax COVID-19 Vaccine Link https://www.fda.gov/media/158912/download
The Vaccines and Related Biological Products Advisory Committee unanimously (one member abstained) voted to grant Emergency Use Authorization to Novavax (the Sponsor) for emergency use authorization (EUA) of the Novavax COVID-19 Vaccine for the treatment in people over the age of 18.
According to Peter Marks, MD, Director of FDA’s Center for Biologics Evaluation and Research: “We do have a problem with vaccine uptake that is very serious in the United States,”. “And anything we can do to get people more comfortable with these potentially life-saving medical products is something that we feel we are compelled to do.” This acknowledgment is a step in the right direction.
Next Steps- FDA will then determine whether to grant the EUA which will most definitely happen. Stay tuned.